Era of molecular diagnosis for pathogen identification of unexplained pneumonia, lessons to be learned

Ai, Jing; Zhang, Yi; Zhang, Hao Cheng; Teng, Xu; Zhang, Wen Hong

doi:10.1080/22221751.2020.1738905

Cited by 78 publications

(70 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A team approach to manage COVID-19 patients Currently, there have been more than 330 laboratoryconfirmed adult cases of COVID-19 in Shanghai [7]. Most patients (>90%) are in mild or moderate states, and more than 90% of them have been cured and discharged by now.…”

Section: Professor Wenhong Zhang (Responsible For Shanghai's Overall mentioning

confidence: 99%

Clinical observation and management of COVID-19 patients

Zhang

2020

Emerging Microbes & Infections

381

340

View full text Add to dashboard Cite

Three leading infectious disease experts in China were invited to share their bedside observations in the management of COVID-19 patients. Professor Taisheng Li was sent to Wuhan to provide frontline medical care. He depicts the clinical course of SARS-CoV-2 infection. Furthermore, he observes the significant abnormality of coagulation function and proposes that the early intravenous immunoglobulin and low molecular weight heparin anticoagulation therapy are very important. Professor Hongzhou Lu, a leader in China to try various anti-viral drugs, expresses concern on the quality of the ongoing clinical trials as most trials are small in scale and repetitive in nature, and emphasizes the importance of the quick publication of clinical trial results. Regarding the traditional Chinese medicine, Professor Lu suggests to develop a creative evaluation system because of the complicated chemical compositions. Professor Wenhong Zhang is responsible for Shanghai's overall clinical management of the COVID-19 cases. He introduces the team approach to manage COVID-19 patients. For severe or critically ill patients, in addition to the respiratory supportive treatment, timely multiorgan evaluation and treatment is very crucial. The medical decisions and interventions are carefully tailored to the unique characteristics of each patient.

show abstract

Section: Professor Wenhong Zhang (Responsible For Shanghai's Overall mentioning

confidence: 99%

Clinical observation and management of COVID-19 patients

Zhang

2020

Emerging Microbes & Infections

381

340

View full text Add to dashboard Cite

show abstract

“…104) and 77 studies(15-29, 32-38, 40-43, 47-52, 55-62, 65-77, 79-94, 96, 98-103) were included in the current systematic review and meta-analysis respectively. 73.3% (66) studies were conducted in China.…”

mentioning

confidence: 99%

Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: a systematic review and meta-analysis

Wong

Tang

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective: To conduct a systematic review and meta-analysis on the comorbidities, symptoms, clinical characteristics and treatment of COVID-19 patients.Method: Epidemiological studies published in 2020 (from January-March) on the clinical presentation, laboratory findings and treatments of COVID-19 patients were identified from PubMed/MEDLINE and Embase databases. Studies published in English by 27th March, 2020 with original data were included. A random-effects model was used to aggregate estimates across eligible studies and produce meta-analytic estimates. Primary outcomes included comorbidities of COVID-19 patients, their symptoms presented on hospital admission, laboratory results and radiological outcomes, and pharmacological and in-patient treatments.Results: 77 studies were included in this meta-analysis, accounting for a total of 11,028 COVID- 19 patients in multiple countries. The most common comorbidities were hypertension (18.1%, 95%CI: 15.4-20.8%). The most frequently identified symptoms were fever (72.4%, 95%CI: 67.2-77.7%) and cough (55.5%, 95%CI: 50.7-60.3%). For pharmacological treatment, 63.9% (95%CI: 52.5-75.3%), 62.4% (95%CI: 47.9-76.8%) and 29.7% (95%CI: 21.8-37.6%) of patients were given antibiotics, antiviral, and corticosteroid, respectively. Notably, 62.6% (95%CI: 39.9- 85.4%) and 20.2% (95%CI: 14.6-25.9%) of in-patients received oxygen therapy and non- invasive mechanical ventilation, respectively.Conclusions: This meta-analysis informed healthcare providers about the timely status of characteristics and treatments of COVID-19 patients across different countries.PROSPERO Registration Number: CRD42020176589

show abstract

“…technique has been used to diagnose COVID-19 in less than an hour without using multiple instruments [117]. A study employed the combination of RT-PCR, CRISPR, and metagenomic nextgeneration sequencing (mNGS) for the detection of SARS-CoV-2 and confirmed the effective clinical diagnosis of COVID-19 [118].…”

Section: Diagnostic Technologiesmentioning

confidence: 99%

Pandemic Coronavirus Disease (COVID-19): Challenges and A Global Perspective

Malik¹,

Kumar²,

Sircar³

et al. 2020

Preprint

View full text Add to dashboard Cite

The technology-driven world of the 21 st century is currently confronted with a major threat to humankind in the form of the coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As of April 22, 2020, COVID-19 has claimed 169, 006 human lives and had spread to over 200 countries with more than 2,471,136 confirmed cases. The perpetually increasing figures associated with COVID-19 are disrupting the social and economic systems globally. The losses are unmatched and significantly higher compared to those from previously encountered pathogenic infections. Previously, two CoVs (SARS-CoV and Middle East respiratory syndrome-CoV) affected the human population in 2002 and 2012 in China and Saudi Arabia, respectively. Based on genomic similarities, animal-origin CoVs, primarily those infecting bats, civet cats, and pangolins, were presumed to be the source of emerging human CoVs, including the SARS-CoV-2. The cohesive approach amongst virologists, bioinformaticians, big data analysts, epidemiologists, and public health researchers across the globe has delivered high-end viral diagnostics. Similarly, vaccines and therapeutics against COVID-19 are currently in the pipeline for clinical trials. The rapidly evolving and popular technology of artificial intelligence played a major role in confirming and countering the COVID-19 pandemic using digital technologies and mathematical algorithms. In this review, we discuss the noteworthy advancements in the mitigation of the COVID-19 pandemic, focusing on the etiological viral agent, comparative genomic analysis, population susceptibility, disease epidemiology, animal reservoirs, laboratory animal models, disease transmission, diagnosis using artificial intelligence interventions, therapeutics and vaccines, and disease mitigation measures to combat disease dissemination.

show abstract

Era of molecular diagnosis for pathogen identification of unexplained pneumonia, lessons to be learned

Cited by 78 publications

References 14 publications

Clinical observation and management of COVID-19 patients

Clinical observation and management of COVID-19 patients

Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: a systematic review and meta-analysis

Pandemic Coronavirus Disease (COVID-19): Challenges and A Global Perspective

Contact Info

Product

Resources

About